Adult chronic immune (idiopathic) thrombocytopenic purpura in splenectomised patients who are refractory to other treatments (eg, corticosteroids & Ig). 2nd-line treatment for adult non-splenectomised patients to whom surgery is contraindicated.
Dosage/Direction for Use
SC inj Initially 1 mcg/kg once wkly, may be increased by increments of 1 mcg/kg until platelet count ≥50 x 109/L is achieved. Max: 10 mcg/kg once wkly.
Hypersensitivity to romiplostim or E. coli-derived proteins.
Recurrence of thrombocytopenia & bleeding after discontinuation. Increased bone marrow reticulin. Thrombotic/thromboembolic complications. Progression of existing myelodysplastic syndrome. Immunogenicity. Alterations in RBC & WBC. May impair ability to drive or operate machinery. Renal & hepatic impairment. Pregnancy & lactation. Childn <18 yr.
Hypersensitivity reactions, headache. Reoccurrence of thrombocytopenia & bleeding after cessation of treatment, increased bone marrow reticulin, thrombotic/thromboembolic complications, progression of existing myelodysplastic syndrome to acute myeloid leukemia.